COVID-19 Update

Combatting Future Viral Threats with Vaccine Advances

The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.

What’s Next for COVID-19 Vaccines and Variants?

More technologies and treatments are emerging for COVID-19—along with new variants.

Key Elements for Assay Transfer Success

Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.

The Necessity of Prioritizing Cleaning Validation

July 01, 2021

With COVID-19 vaccine facilities receiving recent citations, it is evident that failure to meet cleaning and sanitization requirements puts patients, facilities, and operators at risk.

FDA Adds Warning to mRNA Vaccine Fact Sheets

June 28, 2021

Reports of myocarditis and pericarditis following Pfizer-BioNTech and Moderna vaccinations prompts warnings.

EC Orders 150 Million Additional Doses of Moderna’s COVID-19 Vaccine

June 23, 2021

The European Commission has purchased an additional 150 million doses of Moderna’s COVID-19 vaccine for delivery in 2022.

Regeneron’s Antibody Combination Therapy Reduces COVID-19 Mortality Risk

June 21, 2021

RECOVERY trial results have shown that Regeneron’s investigational antibody combination therapy reduces the mortality risk for seronegative hospitalized patients with severe COVID-19.

CureVac Releases Interim Results from COVID-19 Vaccine Candidate Trial

June 18, 2021

CureVac’s first-generation COVID-19 vaccine candidate, CvnCoV, did not meet efficacy targets in a second interim analysis.

Biden Administration Invests in Antiviral Medicines

June 18, 2021

The US government will invest $3 billion from the American Rescue Plan into a COVID-19 antiviral development strategy.

PHE Analysis Demonstrates Efficacy of COVID Vaccines Against Delta Variant

June 18, 2021

Recent analysis has shown that two doses of COVID-19 vaccines are highly effective against hospitalization as a result of infection with the Delta variant of COVID-19.

Process Development Improvements Post-Pandemic

June 15, 2021

What can the biopharma industry learn from its rapid response to the COVID-19 pandemic?

Novavax Reports on Two Vaccine Efficacy Studies

June 15, 2021

Novavax’s COVID-19 vaccine is 90.4% effective and maintains efficacy when administered with an influenza vaccine.

FDA Authorizes Use of Drug Substance for Janssen COVID-19 Vaccine

June 14, 2021

The agency approved two batches of drug substance manufactured at the Emergent BioSolutions facility in Baltimore for use in the Janssen COVID-19 vaccine.